Semaglutide constipation is common: in the Wegovy weight-loss trials it affected 24% of people on the medication, against 11% on placebo. Most of it responds to fiber, fluids and a routine. Here is the plan Arbor's clinicians walk patients through, and the few signs that mean you should not wait it out.
Your cells make glutathione every day, and a handful of habits shape how much. Here is what the research supports, what it does not, and where a clinician fits in.
"Ozempic face" is not a side effect listed in the Ozempic or Wegovy prescribing information. It is a nickname for the hollow, looser look that can follow fast, large weight loss, and the habits that lower the odds are the same ones Arbor's clinicians build into every GLP-1 program.
Your prescription is written in milligrams, your syringe is marked in units, and the number that connects them is printed on your vial. Here is how to read all three and draw the right dose every time.
Most hair loss on a GLP-1 looks like shedding after fast weight loss, and it usually grows back. What people call Ozempic hair loss shows up in the semaglutide and tirzepatide prescribing data too, at rates of 3% to 6% in trials. Here is what causes it, what lowers your odds, and when to raise it with Arbor's clinicians.
Yes. People prescribed both are commonly given the same schedule. Here is how the order and timing get set, what a clean two-injection routine looks like, and what decides each dose.
Natural GLP-1 foods are real, but their effect is measured in minutes and percentages, not weeks. Here are 12 foods studied for GLP-1 in people, ranked by how strong the evidence is, and an honest look at why none of them works like Ozempic.
Switching is one of the most common changes Arbor's clinicians manage, and it does not mean starting over. Here is the standard approach, what the first weeks usually feel like, and how to keep your routine steady while the new medication builds.
The two leading GLP-1 weight loss medications compared at the molecule level. Mechanism, clinical-trial efficacy, side effects, cost, cardiovascular outcomes, and the framework Arbor's clinical team uses to choose between them.